Crude event rates were reported for MI, stroke, ESRD, and major bleeding events
Symptoms of GLP-1 Medication Intolerance The most common symptoms involve the digestive system
All of these issues require further in-depth research, discussion, and augmentation in the future
Using GLP-1 RAs for weight loss control is a relatively new tool for providers to apply to patient care, with Liraglutide and Semaglutide obtaining FDA approval for weight management in non-diabetic populations in 2014 and 2021, respectively (19, 20, 21)
Experience the convergence of science and wellness, and unlock the path to optimal health and vitality
Are there opportunities for product expansion or product tailoring to these users